摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(pyridine-2-sulfonyl)-thiazolidine-2,4-dione | 173019-80-2

中文名称
——
中文别名
——
英文名称
5-(pyridine-2-sulfonyl)-thiazolidine-2,4-dione
英文别名
5-pyridin-2-ylsulfonyl-1,3-thiazolidine-2,4-dione
5-(pyridine-2-sulfonyl)-thiazolidine-2,4-dione化学式
CAS
173019-80-2
化学式
C8H6N2O4S2
mdl
——
分子量
258.279
InChiKey
QMSFFUOFMUISSA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    127
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-(pyridine-2-sulfonyl)-thiazolidine-2,4-dione1-(3,5-bistrifluoromethylphenyl)-3-bromoprop-1-yne正丁基锂 作用下, 生成 5-[3-(3,5-Bis-trifluoromethyl-phenyl)-prop-2-ynyl]-5-(pyridine-2-sulfonyl)-thiazolidine-2,4-dione
    参考文献:
    名称:
    Novel 5-(3-Aryl-2-propynyl)-5-(arylsulfonyl)thiazolidine-2,4-diones as Antihyperglycemic Agents
    摘要:
    Novel 5-(3-aryl-2-propynyl)-5-(arylsulfonyl)th and 5-(3-aryl-2-propynyl)5-(arylsulfonyl)thiazolidine-2,4-diones were prepared and evaluated as oral antihyperglycemic agents in the obese, insulin resistant db/db mouse model at 100 mg/kg and, if the analogue had sufficient potency, 20 mg/kg. The sulfonylthiazolidinediones, 2, were more potent than the corresponding sulfanylthiazolidinedione congeners, 1. With regard to substituent effects on the 3-propynyl phenyl ring (Ar') of 2,4-halogen, substitution generally resulted in the more potent analogues. Substituent effects on the phenylsulfonyl moiety (Ar) of 2 were less clear, although para-halogen substitution on Ar generally was preferable. 2-Pyridinesulfonyl derivatives (Ar = 2-pyridine in 2) also had good potency. Several compounds from series 2 were effective at lowering glucose and insulin in the obese, insulin resistant ob/ob mouse at the 50 mg/kg oral dose. Compound 20 significantly improved the glucose tolerance of obese, insulin resistant Zucker rats at the 20 mg/kg dose level and had no effect on plasma glucose or on glucose tolerance in normal rats fasted for 18 h at the 100 mg/kg level.
    DOI:
    10.1021/jm9706168
  • 作为产物:
    参考文献:
    名称:
    Novel 5-(3-Aryl-2-propynyl)-5-(arylsulfonyl)thiazolidine-2,4-diones as Antihyperglycemic Agents
    摘要:
    Novel 5-(3-aryl-2-propynyl)-5-(arylsulfonyl)th and 5-(3-aryl-2-propynyl)5-(arylsulfonyl)thiazolidine-2,4-diones were prepared and evaluated as oral antihyperglycemic agents in the obese, insulin resistant db/db mouse model at 100 mg/kg and, if the analogue had sufficient potency, 20 mg/kg. The sulfonylthiazolidinediones, 2, were more potent than the corresponding sulfanylthiazolidinedione congeners, 1. With regard to substituent effects on the 3-propynyl phenyl ring (Ar') of 2,4-halogen, substitution generally resulted in the more potent analogues. Substituent effects on the phenylsulfonyl moiety (Ar) of 2 were less clear, although para-halogen substitution on Ar generally was preferable. 2-Pyridinesulfonyl derivatives (Ar = 2-pyridine in 2) also had good potency. Several compounds from series 2 were effective at lowering glucose and insulin in the obese, insulin resistant ob/ob mouse at the 50 mg/kg oral dose. Compound 20 significantly improved the glucose tolerance of obese, insulin resistant Zucker rats at the 20 mg/kg dose level and had no effect on plasma glucose or on glucose tolerance in normal rats fasted for 18 h at the 100 mg/kg level.
    DOI:
    10.1021/jm9706168
点击查看最新优质反应信息

文献信息

  • Certain-[3-aryl-prop-2-ynyl]-5-(arylsulfonyl) thiazolidine -2,4-dione
    申请人:American Home Products Corporation
    公开号:US05574051A1
    公开(公告)日:1996-11-12
    This invention relates to novel 5-[3-aryl-prop-2-ynyl]-5-(arylsulfonyl)- thiazolidine-2,4-diones and 5-[3-aryl-prop-2-ynyl]-5-(arylsulfanyl)thiazolidine-2,4-diones characterized by the general formula (I), seen below, wherein Ar is phenyl, 2-naphthyl, alkyl substituted phenyl, alkoxy substituted phenyl, halogen substituted phenyl, 2-phenyl, substituted 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-quinolinyl, 2-pyrimidinyl, 2-benzoxazolyl, 2-benzthiazolyl, 2-benzimidazolyl, 2-furanyl, 2-benzo-[b]-furanyl, 2-thienyl, 2-benzo-[b]-thienyl; n is 0 or 2; and Ar' is phenyl, alkyl substituted phenyl, perfluoroalkyl substituted phenyl, halogen substituted phenyl, alkoxy substituted phenyl, perfluoroalkoxy substituted phenyl and alkylio substituted phenyl. ##STR1## This invention also relates to the use of the abovementioned compounds in lowering the blood glucose levels in hyperglycemic mammals and pharmaceutical compositions containing the same.
    这项发明涉及新颖的5-[3-芳基-丙-2-炔基]-5-(芳基磺酰基)-噻唑烷-2,4-二酮和5-[3-芳基-丙-2-炔基]-5-(芳基硫基)噻唑烷-2,4-二酮,其具有下面的通用式(I)所示的特征,其中Ar是苯基、2-萘基、烷基取代苯基、烷氧基取代苯基、卤素取代苯基、2-苯基、取代的2-吡啶基、3-吡啶基、4-吡啶基、2-喹啉基、2-嘧啶基、2-苯并噁唑基、2-苯并噻唑基、2-苯并咪唑基、2-呋喃基、2-苯并[ b ]-呋喃基、2-噻吩基、2-苯并[ b ]-噻吩基;n为0或2;Ar'为苯基、烷基取代苯基、全氟烷基取代苯基、卤素取代苯基、烷氧基取代苯基、全氟烷氧基取代苯基和烷氧基取代苯基。该发明还涉及上述化合物在降低高血糖哺乳动物的血糖水平以及含有这些化合物的药物组合物的用途。
  • Anti-hyperglycemic agents
    申请人:American Home Products Corporation
    公开号:US05605918A1
    公开(公告)日:1997-02-25
    This invention relates to novel 5-[3-aryl-prop-2-ynyl]-5-(arylsulfonyl)thiazolidine-2,4-diones and 5-[3-aryl-prop-2-ynyl]-5-(arylsulfanyl)thiazolidine-2,4-diones characterized by the general formula (I), seen below, wherein Ar is phenyl, 2-naphthyl, alkyl substituted phenyl, alkoxy substituted phenyl, halogen substituted phenyl, 2-pyridinyl, substituted 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-quinolinyl, 2-pyrimidinyl, 2-benzoxazolyl, 2-benzthiazolyl, 2-benzimidazolyl, 2-furanyl, 2-benzo-[b]-furanyl, 2-thienyl, or 2-benzo-[b]-thienyl; n is 0 or 2; and Ar' is phenyl, alkyl substituted phenyl, perfluoroalkyl substituted phenyl, halogen substituted phenyl, alkoxy substituted phenyl, perfluoroalkoxy substituted phenyl or alkylthio substituted phenyl: ##STR1## This invention also relates to the use of the abovementioned compounds in lowering the blood glucose levels in hyperglycemic mammals and pharmaceutical compositions containing the same.
    本发明涉及新颖的5-[3-芳基-丙-2-炔基]-5-(芳基磺酰基)噻唑烷-2,4-二酮和5-[3-芳基-丙-2-炔基]-5-(芳基硫基)噻唑烷-2,4-二酮,其特征是具有下面的通式(I),其中Ar是苯基、2-萘基、烷基取代的苯基、烷氧基取代的苯基、卤素取代的苯基、2-吡啶基、取代的2-吡啶基、3-吡啶基、4-吡啶基、2-喹啉基、2-嘧啶基、2-苯并噁唑基、2-苯并噻唑基、2-苯并咪唑基、2-呋喃基、2-苯并[b]-呋喃基、2-噻吩基或2-苯并[b]-噻吩基;n为0或2;Ar'是苯基、烷基取代的苯基、全氟烷基取代的苯基、卤素取代的苯基、烷氧基取代的苯基、全氟烷氧基取代的苯基或烷基硫基取代的苯基: ##STR1## 本发明还涉及上述化合物在降低高血糖哺乳动物的血糖水平和含有它们的制药组合物中的用途。
  • THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS
    申请人:AMERICAN HOME PRODUCTS CORPORATION
    公开号:EP0749430A1
    公开(公告)日:1996-12-27
  • US5574051A
    申请人:——
    公开号:US5574051A
    公开(公告)日:1996-11-12
  • US5605918A
    申请人:——
    公开号:US5605918A
    公开(公告)日:1997-02-25
查看更多

同类化合物

(R)-4-异丙基-2-恶唑烷硫酮 麻黄恶碱 顺-八氢-2H-苯并咪唑-2-酮 顺-1-(4-氟苯基)-4-[1-(4-氟苯基)-4-羰基-1,3,8-三氮杂螺[4.5]癸-8-基]环己甲腈 非达司他 降冰片烯缩醛3-((1S,2S,4S)-双环[2.2.1]庚-5-烯-2-羰基)恶唑烷-2-酮 阿齐利特 阿那昔酮 阿洛双酮 阿帕鲁胺 阿帕他胺杂质2 铟烷-2-YL-甲基胺盐酸 钠2-{[4,5-二羟基-3-(羟基甲基)-2-氧代-1-咪唑烷基]甲氧基}乙烷磺酸酯 重氮烷基脲 詹氏催化剂 解草恶唑 解草噁唑 表告依春 螺莫司汀 螺立林 螺海因氮丙啶 螺[1-氮杂双环[2.2.2]辛烷-8,5'-咪唑烷]-2',4'-二酮 苯甲酸,4-氟-,2-[5,7-二(三氟甲基)-1,8-二氮杂萘-2-基]-2-甲基酰肼 苯氰二硫酸,1-氰基-1-甲基-4-氧代-4-(2-硫代-3-噻唑烷基)丁酯 苯妥英钠杂质8 苯妥英-D10 苯妥英 苯基硫代海因半胱氨酸钠盐 苯基硫代乙内酰脲-谷氨酸 苯基硫代乙内酰脲-蛋氨酸 苯基硫代乙内酰脲-苯丙氨酸 苯基硫代乙内酰脲-色氨酸 苯基硫代乙内酰脲-脯氨酸 苯基硫代乙内酰脲-缬氨酸 苯基硫代乙内酰脲-异亮氨酸 苯基硫代乙内酰脲-天冬氨酸 苯基硫代乙内酰脲-亮氨酸 苯基硫代乙内酰脲-丙氨酸 苯基硫代乙内酰脲-D-苏氨酸 苯基硫代乙内酰脲-(NΕ-苯基硫代氨基甲酰)-赖氨酸 苯基乙内酰脲-甘氨酸 苏氨酸-1-(苯基硫基)-2,4-咪唑烷二酮(1:1) 色氨酸标准品002 膦酸,(2-羰基-1-咪唑烷基)-,二(1-甲基乙基)酯 脱氢-1,3-二甲基尿囊素 聚(d(A-T)铯) 羟甲基-5,5-二甲基咪唑烷-2,4-二酮 羟基香豆素 美芬妥英 美芬妥英